In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report), ...

Maia Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -32.20%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Baird lowered the firm’s price target on Regeneron (REGN) to $759 from $940 and keeps a Neutral rating on the shares. The firms lower target ...